Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Rhea-AI Summary

Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, announced participation in the Goldman Sachs 45th Annual Global Healthcare Conference.

CEO Pascal Touchon and EVP Cokey Nguyen will join a fireside chat on June 12, 2024, at 6:20 a.m. PDT / 9:20 a.m. EDT.

The event will be webcast live on Atara’s website, with an archived replay available for 30 days.

Positive

• Atara Biotherapeutics' participation in the Goldman Sachs 45th Annual Global Healthcare Conference provides significant visibility.
• The live webcast and 30-day replay availability increase accessibility to the company's strategic insights and updates.

Negative

• The press release lacks substantial financial or clinical updates, limiting its immediate impact on investor sentiment.

THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer and Cokey Nguyen, Ph.D., Executive Vice President, Chief Scientific & Technical Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 at 6:20 a.m. PDT / 9:20 a.m. EDT.

A live webcast of the presentation will be available by visiting the Investors and Media section of atarabio.com. An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.

About Atara Biotherapeutics, Inc.

Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of hematological malignancies and B-cell driven autoimmune diseases. Atara is headquartered in Southern California. For more information, visit atarabio.com and follow @Atarabio on X and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240605720457/en/

Investor and Media Relations:

Jason Awe, Ph.D.

Senior Director, Corporate Communications & Investor Relations

(805) 217-2287

jawe@atarabio.com

Source: Atara Biotherapeutics, Inc.

FAQ

What event is Atara Biotherapeutics attending?

Atara Biotherapeutics is participating in the Goldman Sachs 45th Annual Global Healthcare Conference.

When is Atara Biotherapeutics' fireside chat at the Goldman Sachs Healthcare Conference?

The fireside chat is scheduled for June 12, 2024, at 6:20 a.m. PDT / 9:20 a.m. EDT.

Who from Atara Biotherapeutics will attend the Goldman Sachs Healthcare Conference?

CEO Pascal Touchon and EVP Cokey Nguyen will represent Atara Biotherapeutics at the conference.

How can investors view the Atara Biotherapeutics' presentation at the Goldman Sachs Healthcare Conference?

The presentation will be webcast live on Atara's website, with a replay available for 30 days.

What is the stock symbol for Atara Biotherapeutics?

The stock symbol for Atara Biotherapeutics is ATRA.